FMB Wealth Management Invests $228,000 in Astrazeneca Plc $AZN

FMB Wealth Management bought a new position in shares of Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,477 shares of the company’s stock, valued at approximately $228,000.

Other large investors have also modified their holdings of the company. Ledyard National Bank purchased a new stake in shares of Astrazeneca in the fourth quarter valued at about $206,000. Capital Investment Advisory Services LLC grew its holdings in shares of Astrazeneca by 8.0% in the fourth quarter. Capital Investment Advisory Services LLC now owns 3,722 shares of the company’s stock valued at $342,000 after purchasing an additional 276 shares during the period. Center For Asset Management LLC purchased a new stake in shares of Astrazeneca in the fourth quarter valued at about $315,000. Seascape Capital Management grew its holdings in shares of Astrazeneca by 1.2% in the fourth quarter. Seascape Capital Management now owns 48,334 shares of the company’s stock valued at $4,443,000 after purchasing an additional 584 shares during the period. Finally, FRG Family Wealth Advisors LLC grew its holdings in shares of Astrazeneca by 6.0% in the fourth quarter. FRG Family Wealth Advisors LLC now owns 4,557 shares of the company’s stock valued at $419,000 after purchasing an additional 257 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Up 1.8%

Shares of AZN stock opened at $204.44 on Thursday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The stock has a market cap of $317.06 billion, a price-to-earnings ratio of 31.21, a P/E/G ratio of 1.53 and a beta of 0.35. Astrazeneca Plc has a 1-year low of $122.48 and a 1-year high of $212.71.

Astrazeneca Dividend Announcement

The business also recently announced a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were paid a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date of this dividend was Friday, February 20th. Astrazeneca’s dividend payout ratio (DPR) is 66.26%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on AZN shares. HSBC reissued a “buy” rating and issued a $108.00 price objective on shares of Astrazeneca in a report on Wednesday, December 10th. Barclays reissued an “overweight” rating on shares of Astrazeneca in a report on Tuesday, January 6th. Weiss Ratings started coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Wall Street Zen lowered shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Saturday, April 4th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.